source
- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialA phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.Fierce Biotech · 13d ago↗ source
- Opinion: The growing fang-to-pharmacy pipeline“Some of the most powerful medicines we will ever find are already here, carried in the fangs, stingers, and saliva of creatures we’ve been taught to fear,” writes Steve Midway.STAT · 13d ago↗ source
- Opinion: Medicaid and SNAP cuts are exacerbating the intertwined problems of hunger and mental illness“No one built a psychiatric unit to solve hunger,” writes clinical dietician Cole Hanson. But patients come anyway.